Why Is Factor Xa Not a Better Target Than Factor IIa for Therapeutic Inhibition of Coagulation?

Seminars in Thrombosis and Hemostasis

Volumn 29, Issue SUPPL. 1, 2003, Pages 33-36

  Schulman, Sam ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Factor Xa inhibitor; Hemorrhage; Thrombin inhibitor; Thrombosis; Vascular receptors

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; DALTEPARIN; HEPARIN DERIVATIVE; HIRUDIN; HIRULOG; LEPIRUDIN; MELAGATRAN; PROTEINASE; PROTHROMBIN; THROMBIN INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; XIMELAGATRAN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TARGETING; HEMOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; THEORY; THROMBOSIS; TREATMENT OUTCOME;

EID: 0346786477     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-45415     Document Type: Conference Paper

References (12)

1. Carlsson S, Adler G, Elg M. The antithrombotic effects of the oral, direct thrombin inhibitor H 376/95 and other anti-coagulants tested in a deep venous thrombus conscious rat model. Haemostasis 2000;30(suppl 1):166
2. Boström SL, Sarich TC. Effects of melagatran, the active form of the oral, direct thrombin inhibitor H 376/95, and dalteparin, on the endogenous thrombin potential in venous blood from healthy male subjects. Haemostasis 2000;30(suppl 1):22
3. Wolzt M, Boström SL, Wollbratt M, et al. Ximelagatran, an oral direct thrombin inhibitor, normalizes platelet activation and inhibits thrombin generation in patients with non-valvular atrial fibrillation [abstract 263]. Pharmacotherapy 2002;22:1365
4. Eriksson UG, Fager G, Eriksson LM, et al. Effect of acetylsalicylic acid on the pharmacodynamics and pharmacokinetics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran (pINN, formerly H 376/95). Clin Pharmacol Ther 2001;69:24
5. Berntsson P, Mattsson C, Johansson T, Strömqvist M. Enhancement of fibrinolysis by melagatran via inhibition of thrombin-induced activation of pro-CPU (TAFI) [abstract]. Thromb Haemost 2001;86(suppl):P2014
6. Greinacher A, Lubenow N. Recombinant hirudin in clinical practice: focus on lepirudin. Circulation 2000;103:1479-1484
7. Organisation to Assess Strategies for Ischemic Syndromes (OASIS-2) Investigators. Effects of recombinant hirudin (lepirudin) compared with heparin on death, myocardial infarction, refractory angina, and revascularisation procedures in patients with acute myocardial ischaemia without ST elevation: a randomised trial. Lancet 1999;353:429-438
8. Bittl JA, Strony J, Brinker JA, et al. Treatment with bivalirudin (Hirulog) as compared with heparin during coronary angioplasty for unstable or postinfarction angina. Hirulog Angioplasty Study Investigators. N Engl J Med 1995;333:764-769
9. Bittl JA, Chaitman BR, Feit F, Kimball W, Topol EJ. Bivalirudin versus heparin during coronary angiography for unstable or postinfarction angina: final report reanalysis of the Bivalirudin Angioplasty Study. Am Heart J 2001;142:952-959
10. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor on thrombin and fibrinolytic enzymes. Thromb Haemost 1998;79:110-118
11. Klement P, Carlsson S, Rak J, et al. The benefit-to-risk profile of melagatran is superior to that of hirudin in a rabbit arterial thrombosis prevention and bleeding model. J Thromb Haemost 2003;1:587-594
12. Eriksson UG, Bredberg U, Gislén K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young, healthy male subjects. Eur J Clin Pharmacol 2003;59:35-43